Novo Nordisk | NVO - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
ANI Pharmaceuticals USD 4.41M 316K 2025-12
Aurora Cannabis CAD 2.11M 116K 2025-12
Bausch Health Companies USD 397M 15M 2025-12
Bristol-Myers Squibb USD 411M 21M 2026-03
Canopy Growth CAD 7.34M 1.46M 2025-12
Corcept Therapeutics USD 814.88M 809.46M 2026-03
Drreddys Laboratories INR 944M 127M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
GlaxoSmithKline GBP 167M 21M 2026-03
Merck USD 479M 67M 2026-03
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Novartis USD 343M 39M 2026-03
Novo Nordisk DKK 1.53B 3.43B 2025-09
Pacira USD 3.7M 193K 2026-03
Perrigo USD 7.98B 7.94B 2026-03
Phibro Animal Health USD 11.91M 191K 2025-12
Prestige Brands USD 10.67M 636K 2025-12
Sanofi EUR 178M 203M 2026-03
Supernus Pharmaceuticals USD 910K 278K 2023-06
Zoetis USD 62M 5M 2026-03